Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages

  Ko, S Y ^a   Oh, H B ^a   Park, C W ^a   Lee, H C ^a   Lee, J E ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b DNA Link Inc   (South Korea)

Author keywords

Drug resistance mutation; Haplotype analysis; Hepatitis B virus; Ultra deep pyrosequencing

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENE SEQUENCE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; ULTRA DEEP PYROSEQUENCING; VIRUS GENE; VIRUS GENOME;

HEPATITIS B VIRUS;

EID: 84866162632     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03951.x     Document Type: Article

References (21)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
3. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
4. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
5. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712.
6. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145.
7. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46.
8. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437: 376-380.
9. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009; 83: 1718-1726.
10. Margeridon-Thermet S, Shulman NS, Ahmed A et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199: 1275-1285.
11. Cha CH, Sohn YH, Ko SY, Oh HB. Subgenotype and serotype analysis of hepatitis B virus in Korean chronic hepatitis B patients under treatment. Korean J Lab Med 2009; 29: 53-58.
12. Nishijima N, Marusawa H, Ueda Y et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS ONE 2012; 7: e35052, Epub 2012 Apr 16.
13. Bonvin M, Greeve J. Hepatitis B: modern concepts in pathogenesis - APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Curr Opin Infect Dis 2008; 21: 298-303.
14. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
15. Noguchi C, Ishino H, Tsuge M et al. G to A hypermutation of hepatitis B virus. Hepatology 2005; 41: 626-633.
16. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-1514.
17. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
19. Reijnders JG, Deterding K, Petersen J et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
20. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313.
21. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454.